These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 38275876)
1. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma. Abdel-Rahman SA; Gabr M Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275876 [TBL] [Abstract][Full Text] [Related]
2. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities. Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L Front Immunol; 2022; 13():964898. PubMed ID: 35967394 [TBL] [Abstract][Full Text] [Related]
3. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342 [TBL] [Abstract][Full Text] [Related]
4. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages. Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338 [TBL] [Abstract][Full Text] [Related]
5. PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment. Yang M; Wang B; Yin Y; Ma X; Tang L; Zhang Y; Fan Q; Yin T; Wang Y J Control Release; 2023 Jan; 353():63-76. PubMed ID: 36402232 [TBL] [Abstract][Full Text] [Related]
6. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932 [TBL] [Abstract][Full Text] [Related]
7. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. Khan F; Pang L; Dunterman M; Lesniak MS; Heimberger AB; Chen P J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594466 [TBL] [Abstract][Full Text] [Related]
8. Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy. Li J; Yang J; Jiang S; Tian Y; Zhang Y; Xu L; Hu B; Shi H; Li Z; Ran G; Huang Y; Ruan S Biomaterials; 2024 Dec; 311():122708. PubMed ID: 39047538 [TBL] [Abstract][Full Text] [Related]
9. Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma. Jiang S; Li W; Yang J; Zhang T; Zhang Y; Xu L; Hu B; Li Z; Gao H; Huang Y; Ruan S ACS Nano; 2024 Feb; 18(8):6445-6462. PubMed ID: 38358804 [TBL] [Abstract][Full Text] [Related]
10. Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy. Zhou Y; Guo Y; Chen L; Zhang X; Wu W; Yang Z; Li X; Wang Y; Hu Z; Wang Z Theranostics; 2022; 12(12):5488-5503. PubMed ID: 35910792 [No Abstract] [Full Text] [Related]
11. Ferritin light chain promotes the reprogramming of glioma immune microenvironment and facilitates glioma progression. Li H; Yang C; Wei Y; Li X; Jiang W; Xu Y; Li L; Guo R; Chen D; Gao P; Zhang H; Qin H; Zhang Z; Liu X; Yan D Theranostics; 2023; 13(11):3794-3813. PubMed ID: 37441589 [No Abstract] [Full Text] [Related]
12. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment. Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB Front Immunol; 2020; 11():582106. PubMed ID: 33178210 [TBL] [Abstract][Full Text] [Related]
13. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma. Tang L; Zhang M; Liu C Front Immunol; 2022; 13():882257. PubMed ID: 35651605 [TBL] [Abstract][Full Text] [Related]
14. Multiple Synergistic Effects of the Microglia Membrane-Bionic Nanoplatform on Mediate Tumor Microenvironment Remodeling to Amplify Glioblastoma Immunotherapy. Fan Q; Kuang L; Wang B; Yin Y; Dong Z; Tian N; Wang J; Yin T; Wang Y ACS Nano; 2024 Jun; 18(22):14469-14486. PubMed ID: 38770948 [TBL] [Abstract][Full Text] [Related]
15. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment. Wang D; Wang C; Wang L; Chen Y Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355 [TBL] [Abstract][Full Text] [Related]
16. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. Pachocki CJ; Hol EM J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in biomimetic strategies for the immunotherapy of glioblastoma. You H; Geng S; Li S; Imani M; Brambilla D; Sun T; Jiang C Biomaterials; 2024 Dec; 311():122694. PubMed ID: 38959533 [TBL] [Abstract][Full Text] [Related]
18. Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy. Collado J; Boland L; Ahrendsen JT; Miska J; Lee-Chang C Front Immunol; 2024; 15():1336476. PubMed ID: 38380331 [TBL] [Abstract][Full Text] [Related]
19. The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma. Zhang L; Jiang Y; Zhang G; Wei S Front Immunol; 2023; 14():1238233. PubMed ID: 37731483 [TBL] [Abstract][Full Text] [Related]